PL401116A1 - Composition added to infusion fluids - Google Patents
Composition added to infusion fluidsInfo
- Publication number
- PL401116A1 PL401116A1 PL401116A PL40111612A PL401116A1 PL 401116 A1 PL401116 A1 PL 401116A1 PL 401116 A PL401116 A PL 401116A PL 40111612 A PL40111612 A PL 40111612A PL 401116 A1 PL401116 A1 PL 401116A1
- Authority
- PL
- Poland
- Prior art keywords
- amount
- composition
- fluids
- metal compounds
- infusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000003978 infusion fluid Substances 0.000 title abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 3
- 229940088597 hormone Drugs 0.000 abstract 3
- 239000005556 hormone Substances 0.000 abstract 3
- 150000002736 metal compounds Chemical class 0.000 abstract 3
- 239000000243 solution Substances 0.000 abstract 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract 2
- 239000011668 ascorbic acid Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 238000000502 dialysis Methods 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 229910052748 manganese Inorganic materials 0.000 abstract 2
- 239000011572 manganese Substances 0.000 abstract 2
- 239000011669 selenium Substances 0.000 abstract 2
- 229910052711 selenium Inorganic materials 0.000 abstract 2
- 108010037003 Buserelin Proteins 0.000 abstract 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 abstract 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 abstract 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 235000013878 L-cysteine Nutrition 0.000 abstract 1
- 239000004201 L-cysteine Substances 0.000 abstract 1
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract 1
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 102100038803 Somatotropin Human genes 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 abstract 1
- 229960002719 buserelin Drugs 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest kompozycja dodawana do płynów infuzyjnych w szczególności do płynów do przeszczepu, do osocza, do wlewu lub do dializy nerek stosowanych w transplantacji, a także do preparatów krwi i krwiopochodnych oraz płynów stosowanych w dializie otrzewnowej. Kompozycja zawiera w swoim składzie hormony: prolaktynę w ilości od 1,0 ng/l do 10 µg/l lub somatotropinę w ilości od 10 ng/l do 10,0 µg/l lub choriogonadotropinę w ilości od 1,0 ng/l do 1,0 µg/l lub lutropinę w ilości od 10 ng/l do 100,0 µg/l lub folikulotropinę w ilości od 0,01 µg/l do 1,0 µg/l lub buserelinę w ilości od 0,001 µg/l do 1 µg/l. Odmianą jest kompozycja według wynalazku, która zawiera w swoim składzie związki metali takie jak selen lub mangan lub cynk w ilości od 0,0 1 µg/l do 10,0 µg/l. Hormon i związki metali takie jak selen lub mangan rozpuszczony jest w 1-5% roztworze kwasu askorbinowego lub 1-5% roztworze L-cysteiny w warunkach jałowych o pH do wartości 3,5. Hormon i związki metali rozpuszczone w roztworze kwasu askorbinowego i cysteiny przygotowane w warunkach sterylnych w fiolkach są dodawane do znanych płynów przed ich użyciem.The subject of the invention is a composition added to infusion fluids, in particular to transplant fluids, plasma, infusion or kidney dialysis used in transplantation, as well as blood and blood preparations and fluids used in peritoneal dialysis. The composition contains the hormones: prolactin in an amount from 1.0 ng / l to 10 µg / l or somatotropin in an amount from 10 ng / l to 10.0 µg / l or choriogonadotropin in an amount from 1.0 ng / l to 1.0 µg / l or lutropin in the amount from 10 ng / l to 100.0 µg / l or follitropin in the amount from 0.01 µg / l to 1.0 µg / l or buserelin in the amount from 0.001 µg / l to 1 µg / l. A variation is the composition according to the invention which contains in its composition metal compounds such as selenium or manganese or zinc in an amount from 0.0 1 µg / l to 10.0 µg / l. Hormone and metal compounds such as selenium or manganese are dissolved in a 1-5% ascorbic acid solution or 1-5% L-cysteine solution under sterile conditions with a pH value of up to 3.5. Hormone and metal compounds dissolved in a solution of ascorbic acid and cysteine prepared under sterile conditions in vials are added to known liquids before use.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401116A PL401116A1 (en) | 2012-10-09 | 2012-10-09 | Composition added to infusion fluids |
| PCT/PL2013/000118 WO2014058329A1 (en) | 2012-10-09 | 2013-09-20 | Compositions based on hypophyseal hormones for adding to infusion fluids |
| EP13780230.2A EP2906234A1 (en) | 2012-10-09 | 2013-09-20 | Compositions based on hypophyseal hormones for adding to infusion fluids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401116A PL401116A1 (en) | 2012-10-09 | 2012-10-09 | Composition added to infusion fluids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL401116A1 true PL401116A1 (en) | 2014-04-14 |
Family
ID=49474668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401116A PL401116A1 (en) | 2012-10-09 | 2012-10-09 | Composition added to infusion fluids |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2906234A1 (en) |
| PL (1) | PL401116A1 (en) |
| WO (1) | WO2014058329A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL423936A1 (en) * | 2017-12-18 | 2019-07-01 | Biochefa Farmaceutyczny Zakład Naukowo-Produkcyjny Spółka Z Ograniczoną Odpowiedzialnością | Fluid for perfusion and organ preservation and method for producing it |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102236226B1 (en) * | 2013-05-08 | 2021-04-02 | 감브로 룬디아 아베 | Dialysis formulation |
| CN112569340A (en) * | 2020-12-31 | 2021-03-30 | 苏州素仕生物科技有限公司 | Sterile buserelin injection and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL205012A1 (en) | 1978-03-01 | 1979-11-19 | Polski Komitet Normalizacji I | METHOD OF CHECKING HIGH-LOAD TRIGGER SCALES AND THE TEST DEVICE TO USE THIS METHOD |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
| DE60225666T2 (en) * | 2001-01-25 | 2009-04-16 | Bristol-Myers Squibb Co. | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING EPOTHILON ANALOGUE FOR CANCER TREATMENT |
| AU2005291810B2 (en) | 2004-10-07 | 2011-12-08 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| WO2010084384A1 (en) * | 2009-01-26 | 2010-07-29 | Lola Maksumova | Combinations of an antiplatelet agent and an antioxidant for the treatment of vascular disorders |
| RU2423987C1 (en) * | 2009-12-31 | 2011-07-20 | Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО СПХФА Росздрава) | Infusion solution for total blood volume replacement, hydro-electrolytic rebalancing and hematopoiesis process normalisation |
-
2012
- 2012-10-09 PL PL401116A patent/PL401116A1/en not_active IP Right Cessation
-
2013
- 2013-09-20 WO PCT/PL2013/000118 patent/WO2014058329A1/en not_active Ceased
- 2013-09-20 EP EP13780230.2A patent/EP2906234A1/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL423936A1 (en) * | 2017-12-18 | 2019-07-01 | Biochefa Farmaceutyczny Zakład Naukowo-Produkcyjny Spółka Z Ograniczoną Odpowiedzialnością | Fluid for perfusion and organ preservation and method for producing it |
| PL236896B1 (en) * | 2017-12-18 | 2021-02-22 | Biochefa Farmaceutyczny Zakl Naukowo Produkcyjny Spolka Z Ograniczona Odpowiedzialnoscia | Fluid for perfusion and organ preservation and method for producing it |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014058329A8 (en) | 2014-12-31 |
| WO2014058329A1 (en) | 2014-04-17 |
| EP2906234A1 (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014318696B2 (en) | Liquid protein formulations containing organophosphates | |
| JOP20180125B1 (en) | A stable liquid pharmaceutical formula | |
| EA201992155A1 (en) | METHODS OF CRYOGENIC STORAGE | |
| EA201790989A1 (en) | STABLE PREPARATION OF PROTEIN SOLUTION CONTAINING ANTI-VEGF ANTIBODY IN HIGH CONCENTRATION | |
| PH12014502778A1 (en) | Antibody formulation | |
| EA201490817A1 (en) | ETANERCEPT COMPOSITIONS STABILIZED BY METAL IONS | |
| BR112014005487A2 (en) | stable povidone iodine compositions | |
| EP4265296A3 (en) | Pharmaceutical formulation comprising an insulin compound | |
| EA201400827A1 (en) | MATERIALS AND METHODS OF TREATING DIARRHEA | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| MX385335B (en) | LONG-ACTING LOCAL ANESTHETIC FORMULATION. | |
| EA201991023A1 (en) | PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid | |
| NZ710193A (en) | Agent for elevating nitric oxide concentration | |
| NZ752214A (en) | Arsenic compositions | |
| WO2014058329A8 (en) | Compositions based on hypophyseal hormones for adding to infusion fluids | |
| PH12016501117A1 (en) | Pharmaceutical compositions of carotenoid | |
| PL413307A1 (en) | Stabilizing composition for stabilization of silty and clay grounds, method for producing it and method for stabilization of silty and clay grounds | |
| PL408686A1 (en) | Composition added to the infusion fluids | |
| JO3689B1 (en) | Njectable formulations of paracetamol | |
| Rizk | Various toxicities: case report | |
| Moon | Corrigendum to “Positional effects of partisan attachments on candidate position taking”[Elect. Stud. 37 (2015) 99–108] | |
| PL412243A1 (en) | Applications of chiral ionic liquids containing the derivative of (1R,2S,5R)-(-)-menthol | |
| PL413320A1 (en) | Stabilizing composition for stabilization of silty and clay grounds | |
| PL412686A1 (en) | Diluent for rabbit semen and the semen thinned by this diluent | |
| PL406248A1 (en) | Pharmaceutical composition, containing docosahexaenoic acid, and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VDSO | Invalidation of derivated patent or utility model |
Ref document number: 408686 Country of ref document: PL Kind code of ref document: A1 |